DOCSLIB.ORG

Copyright by John William Steele 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copyright by John William Steele 2020 Copyright by John William Steele 2020 The Dissertation Committee for John William Steele Certifies that this is the approved version of the following dissertation: Mechanisms of Impaired Mitochondrial One-carbon Metabolism and Drug Exposures to Valproic Acid or Dolutegravir in Neural Tube Defects Committee: Richard H. Finnell, Co-Supervisor Dean R. Appling, Co-Supervisor Seema Agarwala John B. Wallingford Steven S. Gross Mechanisms of Impaired Mitochondrial One-carbon Metabolism and Drug Exposures to Valproic Acid or Dolutegravir in Neural Tube Defects by John William Steele Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin May 2020 Dedication This dissertation is dedicated to my loving parents, James and Irene Steele. My work would not have been possible without their unfailing support and encouragement. Acknowledgements First, I must thank my mentor, Dr. Richard Finnell, who supported me even in the lowest and most challenging times of my graduate career. I would also like to thank Drs. Bogdan Wlodarczyk and Robert Cabrera, who have been my close mentors and shaped my understanding of science and my scientific approach. Dr. Linda Lin not only assisted me on most of my mouse experiments, but she has also been one of my dearest friends for the last six years. Nellie Chen performed thousands of genotyping reactions contributing to this work and has been the best undergraduate assistant for which a graduate student could ever hope. Xuanye Cao assisted with data analysis on RNA-seq experiments. Drs. Renu Pandey and Stefano Tiziani performed the LC-MS on VPA-treated embryos at Dell Pediatric Research Institute. Gabriel Tukeman assisted with the DTG cell culture experiments, and Dr. Robert Cabrera assisted with flow cytometry. Xue Gu, Jen Gilmore, Neeraj Patel, and Laura Guillen provided administrative support for my projects and made sure I always got paid. I also want to sincerely thank the following current or former members of the Finnell Lab who either assisted directly on my projects or otherwise contributed positively to my graduate experience: Sung-Eun Kim, Tian Tian, Yunping Lei, Hui Wei, Yael Pomerantz, Xiao Han, Jimi Kim, Amanda Vaughn, Manami Toriyama, and Rachel Tittle. I want to thank Sharon Bayliss, John Bayliss, and Dr. Tim George, who contributed significantly to my first publication as a graduate student, and I want to thank Baylor College of Medicine for hosting my graduate research for the last three years. Finally, I would like to thank my committee members, Drs. Dean Appling, Steven Gross, Seema Agarwala, and John Wallingford for their considerate advice and guidance. v Abstract Mechanisms of Impaired Mitochondrial One-carbon Metabolism and Drug Exposures to Valproic Acid or Dolutegravir in Neural Tube Defects John William Steele, Ph.D. The University of Texas at Austin, 2020 Supervisors: Richard H. Finnell and Dean R. Appling Neural tube defects (NTDs) are among the most severe and prevalent human congenital malformations. Their etiology is complex and multifactorial, influenced by dynamically interacting genetic and environmental factors. It is well known that maternal dietary folate status is the greatest modifying factor associated with risk for NTD-affected pregnancies, and that dietary fortification of folic acid (FA) can prevent a significant proportion of NTDs. However, many NTDs have proven to be FA-resistant, presenting a need to understand mechanisms underlying these FA-resistant defects and develop novel intervention strategies targeting this population. A class of FA-resistant NTD mouse models have been developed by inactivating genes associated with mitochondrial one- carbon metabolism (mOCM). Thus, Part One of this work sought to elucidate mechanisms by which impaired mOCM results in FA-resistant NTDs. By crossing mice heterozygous for loss of Slc25a32, a gene coding for the mitochondrial folate transporter, with mice heterozygous for the Crooked Tail (Cd) allele of Lrp6, a gene coding for a Wnt co-receptor, it was discovered that a proportion of resulting co-heterozygous offspring presented with vi NTDs, suggesting a novel digenic interaction between Lrp6 and mOCM. Further experiments demonstrated that Lrp6 regulates expression of mOCM genes in mouse embryos, while CHO cells lacking Slc25a32 demonstrated impaired Wnt signaling rescued by the one-carbon donor, glycine. Building on those data, it was discovered that maternal glycine supplementation could prevent NTDs in Slc25a32 null embryos, and that glycine or serine supplementation may reduce NTDs in Lrp6 Cd mice. Part One experiments also demonstrated that embryonic stem cells lacking Mthfd1l, another mOCM gene, have proliferation defects and are sensitive to hypoxia. Environmental exposure to certain pharmaceutical compounds also increases risk for NTDs. Part Two of this work sought to identify mechanisms of NTD pathology associated with two common pharmaceuticals, the anticonvulsant, valproic acid (VPA), and the HIV integrase inhibitor, dolutegravir (DTG). Untargeted metabolic profiling was performed on VPA-treated mouse embryos, and predictive biomarkers of VPA sensitivity were identified by comparing VPA-affected and unaffected embryos. Other experiments identified a novel, calcium-enhanced interaction between DTG, folate, and folate receptor, suggesting a plausible mechanism by which DTG may enhance NTD risk. vii Table of Contents List of Tables ................................................................................................................... xiii List of Figures ....................................................................................................................xv Chapter 1: Introduction ........................................................................................................1 1.1 Neural Tube Defects .............................................................................................1 1.1.1 Embryology of Neural Tube Defects .....................................................1 1.1.2 Etiology of Neural Tube Defects ...........................................................4 1.1.3 Prevention of Neural Tube Defects .......................................................6 1.2 One-carbon Metabolism .......................................................................................8 1.2.1 Folate .....................................................................................................9 1.2.2 Folate Transport ...................................................................................12 1.2.2.1 Folate Receptors.......................................................................12 1.2.2.2 Reduced Folate Carrier (SLC19A1) ........................................13 1.2.2.3 Proton Coupled Folate Transporter (SLC46A1) ......................14 1.2.2.4 Mitochondrial Folate Transporter (SLC25A32) ......................15 1.2.3 Compartmentalization of One-carbon Metabolism .............................16 1.2.3.1 Mitochondrial One-carbon Metabolism ...................................19 1.2.3.2 Cytosolic One-carbon Metabolism ..........................................22 1.2.3.3 The Methionine Cycle..............................................................23 1.3 Pharmaceutical Exposures and Neural Tube Defects .........................................24 viii PART ONE: MECHANISMS OF IMPAIRED MITOCHONDRIAL ONE-CARBON METABOLISM IN NEURAL TUBE DEFECTS..................................................................28 Chapter 2: Mechanistic Interactions between Lrp6 and Mitochondrial One-carbon Metabolism in Murine Neural Tube Defects ...............................................................29 2.1 Introduction .........................................................................................................29 2.2 Materials and Methods........................................................................................32 2.2.1 Mouse Work ........................................................................................32 2.2.1.1 General .....................................................................................32 2.2.1.2 Genotyping ...............................................................................32 2.2.1.3 Glycine, Serine, and Formate Supplementation Experiments ...................................................................................33 2.2.2 Isolation and Culture of Mouse Embryonic Fibroblasts ......................33 2.2.3 CHO and glyB Cell Culture .................................................................34 2.2.4 TCF/LEF Luciferase Assay .................................................................34 2.2.5 Quantification of Serum Folate............................................................36 2.2.6 RNA Extraction, qPCR, and RNA-seq ................................................37 2.2.6.1 RNA Extraction and Purification from Embryos and CHO Cells ...............................................................................................37 2.2.6.2 cDNA Synthesis and qPCR .....................................................37 2.2.6.3 RNA-seq ..................................................................................38 2.2.7 Statistics ...............................................................................................38 2.3 Results .................................................................................................................39
Load more

Recommended publications
  • Genetics of Amyotrophic Lateral Sclerosis in the Han Chinese
    Genetics of amyotrophic lateral sclerosis in the Han Chinese Ji He A thesis submitted for the degree of Master of Philosophy at The University of Queensland in 2015 The University of Queensland Diamantina Institute 1 Abstract Amyotrophic lateral sclerosis is the most frequently occurring neuromuscular degenerative disorders, and has an obscure aetiology. Whilst major progress has been made, the majority of the genetic variation involved in ALS is, as yet, undefined. In this thesis, multiple genetic studies have been conducted to advance our understanding of the genetic architecture of the disease. In the light of the paucity of comprehensive genetic studies performed in Chinese, the presented study focused on advancing our current understanding in genetics of ALS in the Han Chinese population. To identify genetic variants altering risk of ALS, a genome-wide association study (GWAS) was performed. The study included 1,324 Chinese ALS cases and 3,115 controls. After quality control, a number of analyses were performed in a cleaned dataset of 1,243 cases and 2,854 controls that included: a genome-wide association analysis to identify SNPs associated with ALS; a genomic restricted maximum likelihood (GREML) analysis to estimate the proportion of the phenotypic variance in ALS liability due to common SNPs; and a gene- based analysis to identify genes associated with ALS. There were no genome-wide significant SNPs or genes associated with ALS. However, it was estimated that 17% (SE: 0.05; P=6×10-5) of the phenotypic variance in ALS liability was due to common SNPs. The top associated SNP was within GNAS (rs4812037; p =7×10-7).
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Mitochondrial Genetics
    Mitochondrial genetics Patrick Francis Chinnery and Gavin Hudson* Institute of Genetic Medicine, International Centre for Life, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK Introduction: In the last 10 years the field of mitochondrial genetics has widened, shifting the focus from rare sporadic, metabolic disease to the effects of mitochondrial DNA (mtDNA) variation in a growing spectrum of human disease. The aim of this review is to guide the reader through some key concepts regarding mitochondria before introducing both classic and emerging mitochondrial disorders. Sources of data: In this article, a review of the current mitochondrial genetics literature was conducted using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/). In addition, this review makes use of a growing number of publically available databases including MITOMAP, a human mitochondrial genome database (www.mitomap.org), the Human DNA polymerase Gamma Mutation Database (http://tools.niehs.nih.gov/polg/) and PhyloTree.org (www.phylotree.org), a repository of global mtDNA variation. Areas of agreement: The disruption in cellular energy, resulting from defects in mtDNA or defects in the nuclear-encoded genes responsible for mitochondrial maintenance, manifests in a growing number of human diseases. Areas of controversy: The exact mechanisms which govern the inheritance of mtDNA are hotly debated. Growing points: Although still in the early stages, the development of in vitro genetic manipulation could see an end to the inheritance of the most severe mtDNA disease. Keywords: mitochondria/genetics/mitochondrial DNA/mitochondrial disease/ mtDNA Accepted: April 16, 2013 Mitochondria *Correspondence address. The mitochondrion is a highly specialized organelle, present in almost all Institute of Genetic Medicine, International eukaryotic cells and principally charged with the production of cellular Centre for Life, Newcastle energy through oxidative phosphorylation (OXPHOS).
    [Show full text]
  • Genome-Wide Linkage and Association Study Implicates the 10Q26 Region As a Major Genetic Contributor to Primary Nonsyndromic
    www.nature.com/scientificreports OPEN Genome-wide linkage and association study implicates the 10q26 region as a major Received: 6 July 2017 Accepted: 6 October 2017 genetic contributor to primary Published: xx xx xxxx nonsyndromic vesicoureteric refux John M. Darlow1,2, Rebecca Darlay3, Mark G. Dobson1,2, Aisling Stewart3, Pimphen Charoen4,5, Jennifer Southgate 6, Simon C. Baker 6, Yaobo Xu3, Manuela Hunziker2,7, Heather J. Lambert8, Andrew J. Green1,9, Mauro Santibanez-Koref3, John A. Sayer 3, Timothy H. J. Goodship3, Prem Puri2,10, Adrian S. Woolf 11,12, Rajko B. Kenda13, David E. Barton1,9 & Heather J. Cordell3 Vesicoureteric refux (VUR) is the commonest urological anomaly in children. Despite treatment improvements, associated renal lesions – congenital dysplasia, acquired scarring or both – are a common cause of childhood hypertension and renal failure. Primary VUR is familial, with transmission rate and sibling risk both approaching 50%, and appears highly genetically heterogeneous. It is often associated with other developmental anomalies of the urinary tract, emphasising its etiology as a disorder of urogenital tract development. We conducted a genome-wide linkage and association study in three European populations to search for loci predisposing to VUR. Family-based association analysis of 1098 parent-afected-child trios and case/control association analysis of 1147 cases and 3789 controls did not reveal any compelling associations, but parametric linkage analysis of 460 families (1062 afected individuals) under a dominant model identifed a single region, on 10q26, that showed strong linkage (HLOD = 4.90; ZLRLOD = 4.39) to VUR. The ~9Mb region contains 69 genes, including some good biological candidates.
    [Show full text]
  • Mitochondrial Medicine 2019: Washington DC Scientific and Clinical Meetings June 26-29, 2019 Hilton Alexandria Mark Center Alexandria, VA
    Mitochondrial Medicine 2019: Washington DC Scientific and Clinical Meetings June 26-29, 2019 Hilton Alexandria Mark Center Alexandria, VA 2019 Course Chairs: Amel Kara, MD and Carla Koehler, PhD 2019 CME Chair: Bruce H. Cohen, MD Mitochondrial Medicine 2019: Washington DC Scientific/Clinical Program June 26-29, 2019 Course Description The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited symposium. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS and diabetes. There have been significant advances in the molecular genetics, proteomics, epidemiology and clinical aspects of mitochondrial pathophysiology. This conference is directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program was determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, chart review and new medical knowledge. The format will include didactic lectures from invited experts intermixed with peer-reviewed platform presentations. There will be ample time for professional discussion both in and out of the meeting room, and peer-reviewed poster presentations will be given throughout the meeting. This will be a four-day scientific meeting aimed at those with scientific and
    [Show full text]
  • Downloaded Per Proteome Cohort Via the Web- Site Links of Table 1, Also Providing Information on the Deposited Spectral Datasets
    www.nature.com/scientificreports OPEN Assessment of a complete and classifed platelet proteome from genome‑wide transcripts of human platelets and megakaryocytes covering platelet functions Jingnan Huang1,2*, Frauke Swieringa1,2,9, Fiorella A. Solari2,9, Isabella Provenzale1, Luigi Grassi3, Ilaria De Simone1, Constance C. F. M. J. Baaten1,4, Rachel Cavill5, Albert Sickmann2,6,7,9, Mattia Frontini3,8,9 & Johan W. M. Heemskerk1,9* Novel platelet and megakaryocyte transcriptome analysis allows prediction of the full or theoretical proteome of a representative human platelet. Here, we integrated the established platelet proteomes from six cohorts of healthy subjects, encompassing 5.2 k proteins, with two novel genome‑wide transcriptomes (57.8 k mRNAs). For 14.8 k protein‑coding transcripts, we assigned the proteins to 21 UniProt‑based classes, based on their preferential intracellular localization and presumed function. This classifed transcriptome‑proteome profle of platelets revealed: (i) Absence of 37.2 k genome‑ wide transcripts. (ii) High quantitative similarity of platelet and megakaryocyte transcriptomes (R = 0.75) for 14.8 k protein‑coding genes, but not for 3.8 k RNA genes or 1.9 k pseudogenes (R = 0.43–0.54), suggesting redistribution of mRNAs upon platelet shedding from megakaryocytes. (iii) Copy numbers of 3.5 k proteins that were restricted in size by the corresponding transcript levels (iv) Near complete coverage of identifed proteins in the relevant transcriptome (log2fpkm > 0.20) except for plasma‑derived secretory proteins, pointing to adhesion and uptake of such proteins. (v) Underrepresentation in the identifed proteome of nuclear‑related, membrane and signaling proteins, as well proteins with low‑level transcripts.
    [Show full text]
  • Leigh Syndrome: One Disorder, More Than 75 Monogenic Causes
    REVIEW Leigh Syndrome: One Disorder, More Than 75 Monogenic Causes Nicole J. Lake, MSc,1,2 Alison G. Compton, PhD,1,2 Shamima Rahman, MD, PhD,3 and David R. Thorburn, PhD1,2,4 Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disor- der is genetically heterogeneous, and to date pathogenic mutations in >75 genes have been identified, encoded by 2 genomes (mitochondrial and nuclear). More than one-third of these disease genes have been characterized in the past 5 years alone, reflecting the significant advances made in understanding its etiological basis. We review the diverse biochemical and genetic etiology of Leigh syndrome and associated clinical, neuroradiological, and metabolic features that can provide clues for diagnosis. We discuss the emergence of genotype–phenotype correlations, insights gleaned into the molecular basis of disease, and available therapeutic options. ANN NEUROL 2016;79:190–203 isorders of mitochondrial energy generation are the phenotype relationships for this rare disorder. Advances in Dmost frequent group of inherited metabolic disor- characterizing the genetic basis of LS have consolidated our ders, with an estimated incidence of at least 1 in 5,000 understanding of the molecular basis of disease, revealing a live births.1 The most common clinical presentation of diverse biochemical etiology consistent with the annotation mitochondrial disease in children is a progressive neuro- of LS as a disorder of energy generation.2 degenerative disorder known as Leigh syndrome (LS; Mendelian Inheritance in Man [MIM] 25600). LS has Clinical and Neuroradiological Features 2 an estimated prevalence of 1 per 40,000 live births ; LS is clinically heterogeneous, with significant variation however, much higher incidences have been observed in between patients with respect to age of onset, age of 3,4 specific populations owing to founder mutations.
    [Show full text]
  • MMEJ-Based Precision Gene Editing for Applications in Gene Therapy and Functional Genomics
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.25.060541; this version posted April 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. MMEJ-based Precision Gene Editing for applications in Gene Therapy and Functional Genomics Gabriel Martínez-Gálvez1, Armando Manduca1, and Stephen C. Ekker2,* 1 Department of Biomedical Engineering & Physiology, Mayo Clinic, Rochester, MN, 55905, USA 2 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905, USA * To whom correspondence should be addressed. Tel: +1 507-284-5530; Fax: +1 507-293-1058; Email: [email protected] Biorxiv v1.01 ABSTRACT Experiments in gene editing commonly elicit error-prone non-homologous end joining for DNA double-strand break (DSB) repair. Microhomology-mediated end joining (MMEJ) can generate more predictable outcomes for functional genomic and somatic therapeutic applications. MENTHU is a computational tool that predicts nuclease-targetable sites likely to result in MMEJ-repaired, homogeneous genotypes (PreMAs) in zebrafish. We deployed MENTHU on 5,885 distinct Cas9-mediated DSBs in mouse embryonic stem cells, and compared the predictions to those by inDelphi, another DSB repair predictive algorithm. MENTHU correctly identified 46% of all PreMAs available, doubling the sensitivity of inDelphi. We also introduce MENTHU@4, an MENTHU update trained on this large dataset. We trained two MENTHU-based algorithms on this larger dataset and validated them against each other, MENTHU, and inDelphi.
    [Show full text]
  • Computational Approaches for Understanding One-Carbon
    Computational approaches for understanding one-carbon metabolism in cancer A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Mahya Mehrmohamadi January 2017 © 2017 Mahya Mehrmohamadi ABSTRACT COMPUTATIONAL APPROACHES FOR UNDERSTANDING ONE- CARBON METABOLISM IN CANCER Mahya Mehrmohamadi, Ph. D. Cornell University 2017 Cancer metabolism is an emerging research area in cancer biology and therapeutics. One of the major metabolic pathways known to play important roles in the pathogenesis of cancer is one-carbon (1-C) metabolism. 1-C metabolism integrates the status of many dietary nutrients as inputs, and in turn regulates a variety of cellular processes including de novo nucleotide synthesis, lipid metabolism, protein biosynthesis, redox metabolism, transsulfuration, and epigenetics. As the regulation of these cellular processes is critical to cells, the tuning of the activity of 1-C metabolism plays important roles in cancer. Previous studies have established implications of genetic and dietary perturbations of multiple components of 1-C metabolism in human cancers. However, the heterogeneity among cancer types and subtypes with respect to the usage and flux distribution of 1-C metabolism has not been systematically quantified. There remain great potentials in deciphering how 1-C metabolism plays different roles in different human cancers, especially since this metabolic pathway is targeted by a number of the existing antimetabolite chemotherapeutic agents. In this dissertation, I quantitatively characterize various aspects of 1-C metabolism across human cancers. I first investigate the between-cancer-type variation in the usage of serine by 1-C metabolism using flux distribution analyses and find substantial heterogeneity.
    [Show full text]
  • A Primer Genetic Toolkit for Exploring Mitochondrial Biology and Disease Using
    bioRxiv preprint doi: https://doi.org/10.1101/542084; this version posted February 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 A primer genetic toolkit for exploring mitochondrial biology and disease using 2 zebrafish 3 Ankit Sabharwal1, Jarryd M. Campbell1,2, Zachary WareJoncas1, Mark Wishman1, Hirotaka 4 Ata1,2, Wiebin Liu1.3, Noriko Ichino1, Jake D. Bergren1, Mark D. Urban1, Rhianna Urban1, Tanya 5 L. Poshusta1, Yonghe Ding1,3, Xiaolei Xu1,3, Karl J. Clark1,2, Stephen C. Ekker1,2* 6 1. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, 7 USA 8 2. Center for Clinical and Translational Sciences, Mayo Clinic, Rochester, MN 55905, USA 9 3. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA 10 *Corresponding author: [email protected] 11 Keywords: 12 Mitochondria, Mitochondrial disorders, Zebrafish, gene editing, 13 TALEN, Gene Breaking Transposon 1 bioRxiv preprint doi: https://doi.org/10.1101/542084; this version posted February 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 14 Abstract 15 Mitochondria are a dynamic eukaryotic innovation that play diverse roles in biology and disease. 16 The mitochondrial genome is remarkably conserved in all vertebrates, encoding the same 37 17 gene set and overall genomic structure ranging from 16,596 base pairs (bp) in the teleost 18 zebrafish (Danio rerio) to 16,569 bp in humans.
    [Show full text]
  • Exploring the Possible Mechanism and Drug Targets of Huang-Qi-Gui
    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2020, Article ID 2363262, 12 pages https://doi.org/10.1155/2020/2363262 Research Article Exploring the Possible Mechanism and Drug Targets of Huang-Qi-Gui-Zhi-Wu-Wu Decoction for the Treatment of Chemotherapy-Induced Peripheral Neuropathy on Network Pharmacology Jia-lin Gu ,1,2 Guo-li Wei,1,3 Yu-zhu Ma,1,2 Jin-zhi Zhang,1,2 Yi Ji,1,2 Ling-chang Li,1,3 Jia-lin Yu,1,3 Can-hong Hu,1,3 and Jie-ge Huo 1,3 1Department of Oncology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, China 2Graduate School, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, China 3Department of Oncology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, China Correspondence should be addressed to Jie-ge Huo; [email protected] Received 14 April 2020; Revised 7 November 2020; Accepted 12 November 2020; Published 23 November 2020 Academic Editor: Adolfo Andrade-Cetto Copyright © 2020 Jia-lin Gu et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment, which may influence its successful completion. )e Huang-Qi-Gui-Zhi-Wu-Wu decoction (HQGZWWD) has been widely used to treat CIPN in China although the pharmacological mechanisms involved have not been clarified. Using the network pharmacology approach, this study investigated the potential pathogenesis of CIPN and the therapeutic mechanisms exerted by the HQGZWWD herbal formula in CIPN.
    [Show full text]